Program
BREAK
FORUM
GLOBAL LEADERSHIP FORUM
INVITED SYPOSIUM
MEET THE PROFESSORS
ON-DEMAND SYMPOSIA
OTHER EVENT
PLENARY LECTURE
SPONSORED SYMPOSIUM
SYMPOSIUM
BREAK
FORUM
GLOBAL LEADERSHIP FORUM
INVITED SYPOSIUM
MEET THE PROFESSORS
ON-DEMAND SYMPOSIA
OTHER EVENT
PLENARY LECTURE
SPONSORED SYMPOSIUM
SYMPOSIUM
| Time | Auditorium | Hall 117 | Hall 112 | Hall 115+116 | Hall 113 | Hall 114 | Hall 111 | Hall 212 | VIP ROOM- Level P0 | Exhibition | On-Demand Virtual Gallery | No Hall |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 07:00-08:30 |
ON - DEMAND SYMPOSIA (VIRTUAL GALLERY) - Online Only
|
|||||||||||
| 08:30-10:30 |
INDUSTRY SYMPOSIUM (NONE CME/CPD CREDIT)
|
GLIA IN ACTION: SHAPING ALZHEIMER’S DISEASE
|
DECODING ALZHEIMER’S: GENES, ANCESTRY & OMICS
|
APOE4 ACROSS CELLS AND SYSTEMS: MECHANISMS DRIVING AD
|
PSP: FROM TAU BIOLOGY TO THERAPEUTICS
|
LATE BREAKING SYMPOSIUM
|
INVITED SYMPOSIUM (NONE CME/CPD CREDIT) BY INVITATION ONLY
|
INVITED SYMPOSIUM (NONE CME/CPD CREDIT) BY INVITATION ONLY
|
||||
| 10:30-11:00 |
COFFEE BREAK
|
|||||||||||
| 11:00-13:00 |
INDUSTRY SYMPOSIUM (NONE CME/CPD CREDIT)
|
TRANSFORMING PARKINSON’S: FROM TREATMENT TO PREVENTION
|
FROM SYNAPSES TO NETWORKS IN AD
|
MICROGLIA: SIGNALS, STATES & THERAPEUTIC TARGETS
|
FROM CELLS TO BIOMARKERS
|
LATE BREAKING SYMPOSIUM
|
INVITED SYMPOSIUM (NONE CME/CPD CREDIT) BY INVITATION ONLY
|
INVITED SYMPOSIUM (NONE CME/CPD CREDIT) BY INVITATION ONLY
|
||||
| 13:00-14:00 |
LUNCH & INFORMAL NETWORKING WITH PROFESSORS
|
|||||||||||
| 13:00-14:00 |
MEET THE PROFESSORS 1
|
|||||||||||
| 14:00-15:00 |
INDUSTRY SYMPOSIUM (NONE CME/CPD CREDIT)
|
|||||||||||
| 14:00-15:30 |
AMYLOID & TAU: RETHINKING ALZHEIMER’S PATHOGENESIS
|
CHOLINERGIC VULNERABILITY IN ALZHEIMER’S AND LEWY BODY DISEASE
|
THE GENETIC SPECTRUM OF NEURODEGENERATION: FROM MUTATIONS TO POLYGENIC RISK
|
APOE AND BEYOND: ALZHEIMER’S GENETICS ACROSS ANCESTRIES
|
LATE BREAKING SYMPOSIUM
|
INVITED SYMPOSIUM (NONE CME/CPD CREDIT) BY INVITATION ONLY
|
INVITED SYMPOSIUM (NONE CME/CPD CREDIT) BY INVITATION ONLY
|
|||||
| 15:30-15:45 |
SHORT BREAK
|
|||||||||||
| 15:45-16:45 |
GLOBAL LEADERSHIP FORUM: MOONSHOTS & MILESTONES: WHO WILL OWN THE FUTURE OF NEURODEGENERATION?
|
|||||||||||
| 16:45-16:50 |
SHORT BREAK
|
|||||||||||
| 16:50-17:50 |
PLENARY LECTURE 1, 2
|
|||||||||||
| 17:50-17:55 |
SHORT BREAK
|
|||||||||||
| 17:55-18:40 |
OPENING CEREMONY AND AWARDS
|
|||||||||||
| 18:50-19:50 |
WELCOME RECEPTION IN EXHIBITION
|
|||||||||||
| Time | Auditorium | Hall 117 | Hall 112 | Hall 115+116 | Hall 113 | Hall 114 | Hall 111 | Hall 212 | VIP ROOM- Level P0 | Exhibition | On-Demand Virtual Gallery | Offsite | Exhibition/Product Theater | No Hall |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 07:00-08:00 |
ON - DEMAND SYMPOSIA (VIRTUAL GALLERY) - Online Only
|
|||||||||||||
| 07:00-07:40 |
ADPD RUN FOR THE BRAIN
|
|||||||||||||
| 08:00-09:00 |
PLENARY LECTURE 3, 4
|
|||||||||||||
| 09:00-09:30 |
EXHIBITION, PRODUCT THEATRE ,POSTERS AND COFFEE BREAK
|
|||||||||||||
| 09:00-09:30 |
PRODUCT THEATER 01 - SUPPORTED BY INDUSTRY (NO CME/CPD CREDIT)
|
|||||||||||||
| 09:30-11:30 |
INDUSTRY SYMPOSIUM (NONE CME/CPD CREDIT)
|
RESILIENCE TO ALZHEIMER’S: FROM BIOLOGY TO PREVENTION
|
PATHOBIOLOGY AND BIOMARKERS OF Α-SYNUCLEINOPATHIES
|
CHOLINERGIC CIRCUIT DYSFUNCTION AND THERAPEUTIC TARGETING IN DEMENTIA
|
FROM MODELS TO MEDICINES IN AD
|
RISK, BIOMARKERS AND RESILIENCE IN PRECLINICAL AD
|
EMERGING FLUID BIOMARKERS AND PROTEOMIC SIGNATURES IN AD
|
LATE BREAKING SYMPOSIUM
|
||||||
| 11:30-11:45 |
SHORT BREAK
|
|||||||||||||
| 11:45-13:25 |
INDUSTRY SYMPOSIUM (NONE CME/CPD CREDIT)
|
|||||||||||||
| 13:15-14:15 |
MEET THE PROFESSOR 2
|
|||||||||||||
| 13:30-14:00 |
PRODUCT THEATER 02 - SUPPORTED BY INDUSTRY (NO CME/CPD CREDIT)
|
|||||||||||||
| 13:35-14:35 |
EXHIBITION, PRODUCT THEATRE ,POSTERS, LUNCH & INFORMAL NETWORKING WITH PROFESSORS
|
|||||||||||||
| 14:35-16:35 |
INDUSTRY SYMPOSIUM (NONE CME/CPD CREDIT)
|
GENETIC RISK, MOLECULAR MECHANISMS AND DISEASE PROGRESSION IN SYNUCLEINOPATHIES
|
APOE-DEPENDENT MECHANISMS ACROSS NEURODEGENERATIVE DISEASES
|
METABOLIC DYSREGULATION ACROSS ALZHEIMER’S AND SYNUCLEINOPATHIES
|
NEUROVASCULAR DYSFUNCTION AND CEREBRAL AMYLOID ANGIOPATHY IN AD
|
FROM PHENOTYPE TO BIOLOGY IN SYNUCLEINOPATHIES
|
PD: PREDICTING PROGRESSION, TREATMENT RESPONSE & REAL-WORLD OUTCOMES
|
|||||||
| 14:35-15:35 |
BIOMARKERS THAT DECIDE: ARE WE READY TO TREAT BEFORE SYMPTOMS?
|
|||||||||||||
| 15:40-16:40 |
AI → IMPACT: CAN DATA-DRIVEN BIOLOGY DELIVER REAL DISEASE-MODIFYING THERAPIES??
|
|||||||||||||
| 16:40-17:40 |
POSTER NETWORKING - SHIFT 1
|
|||||||||||||
| 16:50-17:20 |
PRODUCT THEATRE
|
|||||||||||||
| 16:50-18:30 |
INDUSTRY SYMPOSIUM (NONE CME/CPD CREDIT)
|
|||||||||||||
| Time | Auditorium | Hall 117 | Hall 112 | Hall 115+116 | Hall 113 | Hall 114 | Hall 111 | Hall 212 | VIP ROOM- Level P0 | Exhibition | On-Demand Virtual Gallery | Exhibition/Product Theater |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 07:00-08:30 |
ON - DEMAND SYMPOSIA (VIRTUAL GALLERY) - Online Only
|
|||||||||||
| 08:30-09:00 |
PLENARY LECTURE 5
|
|||||||||||
| 09:00-09:10 |
SHORT BREAK
|
|||||||||||
| 09:10-11:10 |
INDUSTRY SYMPOSIUM (NONE CME/CPD CREDIT)
|
FROM BIOMARKERS TO DIAGNOSIS: TRANSFORMING DEMENTIA CARE
|
ARTIFICIAL INTELLIGENCE AND DIGITAL TECHNOLOGIES IN NEURODEGENERATIVE DISEASES
|
FROM CAA TO ARIA: UNDERSTANDING VASCULAR VULNERABILITY
|
NEUROPATHOLOGICAL HETEROGENEITY AND IN VIVO DETECTION OF NEURODEGENERATIVE PROTEINOPATHIES
|
MAPPING AD PROGRESSION: FROM PATHOLOGY TO NEURODEGENERATION
|
REWRITING NEURODEGENERATION: FROM PROTEIN TARGETING TO GENE EDITING
|
SYMPOSIUM
|
||||
| 11:10-11:40 |
EXHIBITION, PRODUCT THEATRE ,POSTERS AND COFFEE BREAK
|
|||||||||||
| 11:10-11:40 |
PRODUCT THEATER 03 - SUPPORTED BY INDUSTRY (NO CME/CPD CREDIT)
|
|||||||||||
| 11:40-13:20 |
INDUSTRY SYMPOSIUM (NONE CME/CPD CREDIT)
|
|||||||||||
| 13:20-14:20 |
EXHIBITION, PRODUCT THEATRE ,POSTERS, LUNCH & INFORMAL NETWORKING WITH PROFESSORS
|
|||||||||||
| 13:20-14:20 |
MEET THE PROFESSORS 3
|
|||||||||||
| 13:30-14:00 |
PRODUCT THEATER 04 - SUPPORTED BY INDUSTRY (NO CME/CPD CREDIT)
|
|||||||||||
| 14:20-16:20 |
INDUSTRY SYMPOSIUM (NONE CME/CPD CREDIT)
|
CENTRAL AND PERIPHERAL IMMUNE MECHANISMS IN NEURODEGENERATIVE DISEASE
|
BIOMARKERS ACROSS THE SYNUCLEINOPATHY CONTINUUM
|
GENETIC, BIOMARKER AND IMAGING HETEROGENEITY OF CEREBRAL SMALL-VESSEL DISEASE
|
MOLECULAR MECHANISMS AND THERAPEUTIC TARGETING OF LRRK2 IN PD
|
THE VULNERABLE SYNAPSE: FROM MECHANISMS TO BIOMARKERS
|
SYMPOSIUM
|
|||||
| 14:20-15:20 |
OPTIMISING THERAPY: PROMISING COMBINATION STRATEGIES IN AD AND PD
|
|||||||||||
| 15:25-16:25 |
REWIRING THE FAILING BRAIN: CAN CIRCUIT-BASED THERAPIES DELIVER THE NEXT GENERATION OF CNS DRUGS?
|
|||||||||||
| 16:20-16:50 |
EXHIBITION, PRODUCT THEATRE ,POSTERS AND COFFEE BREAK
|
|||||||||||
| 16:20-16:50 |
PRODUCT THEATER 05 - SUPPORTED BY INDUSTRY (NO CME/CPD CREDIT)
|
|||||||||||
| 16:50-17:50 |
INDUSTRY SYMPOSIUM (NONE CME/CPD CREDIT)
|
PROTEOSTASIS AND MOLECULAR MECHANISMS OF TAU PATHOLOGY IN AD
|
MITOCHONDRIA, METABOLISM & NEURODEGENERATION
|
THE NEXT ERA OF AD TREATMENT
|
THE BIOLOGY OF COGNITIVE RESILIENCE
|
MRI BIOMARKERS OF PRODROMAL AND EARLY PARKINSON’S DISEASE
|
MOLECULAR FINGERPRINTS OF NEURODEGENERATION
|
SYMPOSIUM
|
||||
| Time | Auditorium | Hall 117 | Hall 112 | Hall 115+116 | Hall 113 | Hall 114 | Hall 111 | Hall 212 | VIP ROOM- Level P0 | Exhibition | On-Demand Virtual Gallery | No Hall | Exhibition/Product Theater |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 07:00-08:30 |
ON - DEMAND SYMPOSIA (VIRTUAL GALLERY) - Online Only
|
||||||||||||
| 08:00-08:30 |
PLENARY LECTURE 6
|
||||||||||||
| 08:30-08:40 |
SHORT BREAK
|
||||||||||||
| 08:40-10:40 |
INDUSTRY SYMPOSIUM (NONE CME/CPD CREDIT)
|
TARGETING TAU: FROM BIOLOGY TO THERAPY
|
FROM DETECTION TO DIFFERENTIATION IN SYNUCLEINOPATHIES
|
LONGITUDINAL AND MULTIMODAL BIOMARKERS ACROSS THE ALZHEIMER’S DISEASE CONTINUUM
|
THE AGING BRAIN: RESILIENCE, RISK & NEURODEGENERATION
|
PATHOGENS, PROTEINOPATHIES & THE BRAIN
|
TRACKING α-SYNUCLEIN ACROSS THE DISEASE CONTINUUM: FROM TISSUE TO FLUID BIOMARKERS
|
FROM BLOOD AND IMAGING BIOMARKERS TO DIGITAL ENDPOINTS: MULTIMODAL PRECISION DIAGNOSTICS ACROSS AD AND PD
|
|||||
| 10:40-11:10 |
EXHIBITION, PRODUCT THEATRE ,POSTERS AND COFFEE BREAK
|
||||||||||||
| 10:40-11:10 |
PRODUCT THEATER 06 - SUPPORTED BY INDUSTRY (NO CME/CPD CREDIT)
|
||||||||||||
| 11:10-12:50 |
INDUSTRY SYMPOSIUM (NONE CME/CPD CREDIT)
|
||||||||||||
| 12:50-13:50 |
EXHIBITION, PRODUCT THEATRE ,POSTERS, LUNCH & INFORMAL NETWORKING WITH PROFESSORS
|
||||||||||||
| 12:50-13:50 |
MEET THE PROFESSORS 4
|
PRODUCT THEATER 07 - SUPPORTED BY INDUSTRY (NO CME/CPD CREDIT)
|
|||||||||||
| 13:50-15:50 |
INDUSTRY SYMPOSIUM (NONE CME/CPD CREDIT)
|
MECHANISMS AND THERAPEUTICS IN THE ALS–FTD SPECTRUM
|
THE CHANGING ARCHITECTURE OF THE BRAIN
|
ANTI-AMYLOID IMMUNOTHERAPY: BIOLOGICAL EFFECTS & REAL-WORLD PRACTICE
|
SEX- AND APOE-DEPENDENT MECHANISMS OF AD RISK AND PROGRESSION
|
TAU HETEROGENEITY ACROSS THE DISEASE CONTINUUM: FROM MOLECULAR SPECIES TO PATHOLOGY
|
BREAKING THE BLOOD–BRAIN BARRIER: NEXT-GENERATION THERAPEUTIC DELIVERY FOR NEURODEGENERATIVE DISEASES
|
||||||
| 13:50-14:50 |
BIOMARKERS AND DISEASE MODIFICATION IN PD: TARGETING ALPHA-SYNUCLEIN, LRRK2 AND GBA
|
||||||||||||
| 14:52-15:52 |
PRECISION NEUROLOGY: MATCHING THE RIGHT DRUG TO THE RIGHT PATIENT—FROM BIOMARKERS TO CLINICAL REALITY
|
||||||||||||
| 15:50-16:05 |
SHORT BREAK
|
||||||||||||
| 16:05-17:05 |
INDUSTRY SYMPOSIUM (NONE CME/CPD CREDIT)
|
||||||||||||
| 16:05-17:00 |
BEYOND ONE TARGET: TACKLING MIXED PROTEINOPATHIES
|
FROM DISCOVERY TO PRECISION CARE
|
MICROGLIA IN COMMAND: REPROGRAMMING THE BRAIN–IMMUNE AXIS—BREAKTHROUGHS, TARGETS, AND RISKS
|
Α-SYNUCLEIN BIOLOGY, LIPID METABOLISM AND NEURODEGENERATIVE CO-PATHOLOGY
|
MICROBIOME–GUT–BRAIN MECHANISMS IN AD AND PD
|
ENDO-LYSOSOMAL DYSFUNCTION AND IMPAIRED CELLULAR CLEARANCE IN NEURODEGENERATIVE DISEASE
|
RETHINKING MODELS OF NEURODEGENERATION: FROM MECHANISMS TO HUMAN RELEVANCE
|
||||||
| 17:00-17:30 |
PRODUCT THEATRE
|
||||||||||||
| 17:00-18:00 |
POSTER NETWORKING - SHIFT 2
|
||||||||||||
| 17:20-19:00 |
INDUSTRY SYMPOSIUM (NONE CME/CPD CREDIT)
|
||||||||||||
| Time | Hall 117 | Hall 112 | Hall 115 | Hall 116 | Hall 113 | Hall 114 | Hall 111 | Hall 212 | Exhibition | On-Demand Virtual Gallery |
|---|---|---|---|---|---|---|---|---|---|---|
| 07:00-08:30 |
ON - DEMAND SYMPOSIA (VIRTUAL GALLERY) - Online Only
|
|||||||||
| 08:30-09:00 |
PLENARY LECTURE 7
|
|||||||||
| 09:00-09:10 |
SHORT BREAK
|
|||||||||
| 09:10-11:10 |
INDUSTRY SYMPOSIUM (NONE CME/CPD CREDIT)
|
TAU UNDER STRESS: FROM CELLULAR DEFENSE TO NETWORK DYSFUNCTION
|
Α-SYNUCLEIN: STRUCTURE, SEEDING & HETEROGENEITY
|
ANTI-AMYLOID THERAPY: FROM TRIALS TO THE REAL WORLD
|
AD, PD AND LEWY BODY DISORDERS: NOVEL THERAPIES
|
FROM BLOOD TO BRAIN: MAPPING THE BIOLOGY OF DEMENTIA.
|
NOVEL MOLECULAR MECHANISMS AND THERAPEUTIC TARGETS IN NEURODEGENERATION
|
|||
| 10:15-11:15 |
SYMPOSIUM
|
|||||||||
| 11:10-11:50 |
EXHIBITION, PRODUCT THEATRE ,POSTERS AND COFFEE BREAK
|
|||||||||
| 11:50-13:50 |
INDUSTRY SYMPOSIUM (NONE CME/CPD CREDIT)
|
EXPANDING THE AD THERAPEUTIC LANDSCAPE
|
IMAGING, BIOMARKERS, DIAGNOSTICS: CSF- AND BLOOD-BASED BIOMARKERS
|
MAPPING TAU: FROM MOLECULAR SIGNATURES TO SPATIAL LANDSCAPES
|
ANTI-AMYLOID THERAPY: FROM BRAIN DELIVERY AND BIOLOGICAL RESPONSE TO DISEASE MODIFICATION
|
AD: IMAGING, BIOMARKERS, DIAGNOSTICS: STRUCTURAL MRI, MR SPECTROSCOPY
|
EMERGING THERAPIES ACROSS AD, PD, LBD, MSA
|
SYMPOSIUM
|
||
| 13:55-14:05 |
CLOSING SESSION
|
|||||||||